51498-33-0

Basic information

• Product Name: 4-AMINO-CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER
• Synonyms: 4-AMINO-CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER;Cyclohexanecarboxylic acid, 4-aMino-, ethyl ester;Ethyl 4-aMinocyclohexanecarboxylate
• CAS NO: 51498-33-0
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.238
• Mol File: 51498-33-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 235.3°C at 760 mmHg
• Flash Point: 101.5°C
• Appearance: /
• Density: 1.018g/cm³
• Vapor Pressure: 0.0505mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.36±0.70(Predicted)
• CAS DataBase Reference: 4-AMINO-CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER(51498-33-0)
• EPA Substance Registry System: 4-AMINO-CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER(51498-33-0)

Safety Data

• Hazardous Substances Data: 51498-33-0(Hazardous Substances Data)

Usage

General Description

4-Amino-Cyclohexanecarboxylic Acid Ethyl Ester is a chemical compound that can be synthesized through various chemical reactions. Its presence as an ethyl ester form signifies that it's a product of esterification, a reaction between carboxylic acid and alcohol. Its structure comprises a cyclohexane ring, characteristic of the cyclohexane series of organic compounds, and an amino group which consists of a basic nitrogen atom with a lone pair. 4-AMINO-CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER may potentially have applications in the field of organic synthesis or drug design, but its specific properties and uses would need to be further explored and evaluated through research and experimentation.

InChI:InChI=1/C9H17NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h7-8H,2-6,10H2,1H3

Upstream product

• 94-09-7 p-aminoethylbenzoate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 1776-53-0 4-aminocyclohexanecarboxylic acid 
• 57555-71-2 4-hydroxyimino-cyclohexanecarboxylic acid 
• 150-13-0 4-amino-benzoic acid 
• 90942-89-5 ethyl 4-(hydroxyimino)cyclohexane-1-carboxylate 
• 64-17-5 ethanol 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 

Downstream Products

• 33059-86-8 N--N'-<2-chlor-aethyl>-harnstoff 
• 13908-22-0 4-[3-(2-Chloro-ethyl)-ureido]-cyclohexanecarboxylic acid ethyl ester 
• 117112-21-7 C₁₃H₂₄Cl₃N₂O₃P 
• 117130-96-8 C₁₁H₂₂ClN₂O₃P 
• 820232-35-7 ethyl 4-benzyloxycarbonylaminocyclohexanecarboxylate 
• 509093-85-0 ethyl (1s,4s)-4-((4-fluoro-2-nitrophenyl)amino)cyclohexane-1-carboxylate 
• 137864-30-3 Ethyl cis-4-[(2'-cyanobiphenyl-4-yl)methylamino]cyclohexane-1-carboxylate 
• 1296654-04-0 ethyl 4-{[(4-hydroxy-1-methyl-2-oxo-1,2-dihydropyridazino[1,6-a]indol-3-yl)carbonyl]amino}cyclohexanecarboxylate 
• 3306-69-2 2-aza-bicyclo[2.2.2]octan-3-one 

Relevant articles and documents

PROCESS FOR THE DIRECT AMINATION OF ALCOHOLS USING AMMONIA TO FORM PRIMARY AMINES BY MEANS OF A XANTPHOS CATALYST SYSTEM

The present invention relates to a chemocatalytic liquid-phase process for the direct one-stage amination of alcohols to primary amines by means of ammonia in high yields using a catalyst system containing at least one transition metal compound and a xantphos ligand.

ANTIBACTERIAL COMPOUNDS

The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.